Changes in Sexual Behavior and STI Diagnoses Among MSM Initiating PrEP in a Clinic Setting
- PMID: 30117076
- PMCID: PMC6368873
- DOI: 10.1007/s10461-018-2252-9
Changes in Sexual Behavior and STI Diagnoses Among MSM Initiating PrEP in a Clinic Setting
Abstract
We examined changes in sexual behavior and sexually transmitted infection (STI) prevalence among 183 men who have sex with men (MSM) initiating pre-exposure prophylaxis (PrEP) at an STD Clinic in Seattle, WA. We used generalized estimating equations to measure changes in sexual behavior during PrEP use, and linked PrEP patient data with STI surveillance data to compare the prevalence of chlamydia, gonorrhea, and early syphilis in the periods prior to and during PrEP use. Reporting never using condoms in the prior 30 days increased (adjusted relative risk = 1.46; 95% confidence interval 1.13, 1.88) at 12 months after PrEP initiation compared to the initial PrEP visit. Reporting unknown status partners in the prior 30 days decreased at 12 months compared to the initial PrEP visit, but there was no change in number of sexual partners or reporting HIV-positive or HIV-negative partners. The percentage of patients diagnosed with any STI while using PrEP (49.2%) was higher than the percentage diagnosed in the 12 months prior to PrEP use (35.0%), likely driven in part by increased STI screening during PrEP use. Among MSM on PrEP, we observed decreases in condom use, and a higher prevalence of STIs during PrEP use compared to prior to PrEP initiation.
Keywords: HIV; Men who have sex with men; Pre-exposure prophylaxis; Sexual behavior; Sexually transmitted infections.
Conflict of interest statement
Conflict of Interest: CMK, MRG, LAB and LEM have received donations of specimen collection kits and reagents from Hologic, Inc. unrelated to this work. LEM has received speaker’s fees from Hologic, Inc. unrelated to this work. JCD has conducted studies unrelated to this work funded by grants to the University of Washington from Hologic, Curatek, and Quidel, and has received a speaker’s honorarium and travel support for a meeting on retention in HIV care from Gilead. MRG has received research support from GlaxoSmithKline. MAM, SD, and AD declare that they have no conflict of interest.
References
-
- Centers for Disease Control and Prevention. HIV Surveillance Report: Diagnoses of HIV Infection in the United States and Dependent Areas, 2016 Atlanta; 2016.
-
- McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet (London, England). McCormack et al. Open Access article distributed under the terms of CC BY; 2015;387(10013):53–60. - PMC - PubMed
-
- Marcus JL, Volk JE, Pinder J, Liu AY, Bacon O, Hare CB, et al. Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings. Curr HIV/AIDS Rep 2016;13(2):116–24. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous